A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

NCT04427787 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Well Differentiated Neuroendocrine Neoplasm
Neuroendocrine Tumors

Interventions

DRUG: Cabozantinib
DRUG: Lanreotide

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano